Aptamer developed by HKBU for treating rare bone disease 'X-linked hypophosphatemia' receives Orphan Drug Designation and Rare Pediatric Disease Designation by U.S. FDA

Hong Kong Baptist University Hong Kong New York United Kingdom

View original content:https://www.prnewswire.co.uk/news-releases/aptamer-developed-by-hkbu-for-treating-rare-bone-disease-x-linked-hypophosphatemia-receives-orphan-drug-designation-and-rare-pediatric-disease-designation-by-us-fda-302338170.html